<DOC>
	<DOCNO>NCT00409578</DOCNO>
	<brief_summary>The purpose study test hypothesis inhibition renin-angiotensin-aldosterone system ( RAAS ) angiotensin receptor blocker valsartan renin antagonist aliskiren improve ventricular hemodynamics , reflect great reduction level N-terminal proB-type natriuretic peptide ( NT-proBNP ) compare placebo subject stabilize follow acute coronary syndrome ( ACS ) determine high risk due elevate concentration natriuretic peptide .</brief_summary>
	<brief_title>Efficacy Safety Aliskiren Valsartan Versus Placebo Patients Stabilized Following Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male female outpatient 18 year old old Subjects hospitalize ischemic chest discomfort rest last least 10 minute consistent cardiac ischemia Final diagnosis acute coronary syndrome Elevated concentration natriuretic peptide 310 day admission qualify acute coronary syndrome event Known suspect contraindication , include history allergy hypersensitivity angiotensin receptor blocker ( ARBs ) , renin antagonist , drug similar chemical structure . Presence clinically overt heart failure Known evidence leave ventricular systolic dysfunction Percutaneous coronary intervention ( PCI ) less 24 hour randomization . Patients chronic ACEI ARB therapy therapy ACEI ARB clinically require reasonable alternative therapy available . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Post acute coronary syndrome</keyword>
	<keyword>Acute</keyword>
	<keyword>coronary syndrome</keyword>
	<keyword>B-type natriuretic peptide</keyword>
	<keyword>N-terminal</keyword>
	<keyword>pro-B-type natriuretic peptide</keyword>
	<keyword>myocardial infarction</keyword>
</DOC>